[EN] BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] COMPOSES BICYCLIQUES DE PYRAZOLYLE ET D'IMIDAZOLYLE EN TANT QUE LIGANDS DES RECEPTEURS CANNABINOIDES ET LEURS UTILISATIONS
申请人:PFIZER PROD INC
公开号:WO2005061506A1
公开(公告)日:2005-07-07
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
[EN] BICYCLIC PYRAZOL-4-ONE CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] COMPOSES BICYCLIQUES DE PYRAZOL-4-ONE EN TANT QUE LIGANDS DES RECEPTEURS CANNABINOIDES ET LEURS UTILISATIONS
申请人:PFIZER PROD INC
公开号:WO2005061507A1
公开(公告)日:2005-07-07
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein to formula (I).
[EN] PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS<br/>[FR] COMPOSES PURINIQUES ET LEURS UTILISATIONS COMME LIGANDS DE RECEPTEURS DES CANNABINOIDES
申请人:PFIZER PROD INC
公开号:WO2004037823A1
公开(公告)日:2004-05-06
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
本文描述了作为大麻素受体配体的化合物(I)及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
申请人:——
公开号:US20030069259A1
公开(公告)日:2003-04-10
The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and methods of using the same as antiproliferative agents or to prevent apoptosis.
[wherein n represents an integer of from 1 to 4, R1 represents substituted or unsubstituted lower alkyl, -C(=Y)R9 or the like, R2 represents a hydrogen atom, substituted or unsubstituted lower alkyl or the like, R3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group or the like, and R4 represents halogen or the like.]
A phosphodiesterase 10A inhibitor which comprises a quinoline derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient is provided.